Vaccine boosts immune attack on cervical cancer in new trial
NCT ID NCT04580771
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 32 times
Summary
This phase 2 trial tests whether adding an experimental vaccine called PDS0101 to standard chemoradiation is safe and helps control advanced cervical cancer. The vaccine is designed to train the immune system to recognize and attack HPV-infected cancer cells. About 22 adults with stage IB3-IVA cervical cancer will receive the vaccine alongside cisplatin chemotherapy and radiation therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE IB3 CERVICAL CANCER FIGO 2018 are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PDS0101 vaccine (with cisplatin chemotherapy and radiation therapy)
What this could lead to
If successful, this combination could offer a more effective way to control advanced cervical cancer by boosting the immune system's attack on tumor cells.
What could go wrong
This is a small, early-phase trial (22 participants) focused on safety, not yet proven to work. Side effects from the vaccine, chemo, and radiation may be significant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.